Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Novocure Ltd
NVCR
NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.8B
$17.20
▲ +9.00%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$9.82 - $18.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 11.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Tumor Treating Fields technology with patent protection
- First-mover advantage in TTFields oncology applications
- Expanding clinical evidence across multiple solid tumor indications
- Global commercialization infrastructure and regulatory approvals
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion into new cancer indications through clinical trials
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+49.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NVCR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 23, 2026
APR 30, 2026
Reported EPS of -$0.62 vs -$0.51 consensus (-21.1% surprise). Revenue of $174.1M vs $167.8M expected (+3.8%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-21.1%
Next: Apr 23, 2026
Revenue trend · last 8Q
—
—
+21%
+12%
+6%
+8%
+8%
+12%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$150.4M
$155.1M
$161.3M
$155.0M
$158.8M
$167.2M
$174.3M
$174.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-40.9%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · May 4, 2026